Sanofi Genzyme
Sanofi Genzyme is a pharmaceutical company and its products and services are focused on areas such as rare inherited disorders, kidney disease, cancer, transplant and immune disease.
Established in 2001, Genzyme Waterford is situated on a 37-acre site in Waterford. This multi-phased biopharmaceutical facility has seen capital investment of over €500 million.
It is a state-of-the-art facility that serves patients across more than 70 countries. Additional products continue to be developed and introduced to the site with the current expansion set to bring the first Sanofi insulin products to the facility.
Since Sanofi’s acquisition of Genzyme in 2011, the Waterford site has become more closely aligned with the Sanofi network in Europe .
Financial Data
-
31st Dec 18 Source: CRO
- €839.5 million turnover
-
€95.8 million
profit - 684 employees
-
31st Dec 17 Source: CRO
- €981.7 million turnover
-
€272.6 million
profit - 615 employees
- 11 more years available »
Ranking
By Turnover
(€839.5 million)- 104th in Top Companies
- 12th in Pharma
By Employees
(684)- 279th in Top Companies
- 23rd in Pharma
-
- 684
- €839.5 million
Employees
- Johannes Schweppenhäuser Country Manager
Latest News
- Apr 08 Finance ministers gather as fears grow even the future of the euro zone is at risk
- Apr 08 Global stocks higher as investors eye euro-zone finance ministers
- Apr 08 Ibec chief says 10% jobless rate at year end would be ‘great achievement’
- Apr 08 Toast believed to have cut its Dublin staff by 50%
- Apr 08 Covid-19: Government announces €1bn in supports for businesses